This database contains 384 studies, archived under the term: "Other"
Click here to filter this large number of results.
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, Norman R.,
Szabo, Paul,
Adamiak, Basia,
Burgut, Tuna,
Monthe, Carmen,
Lent, Richard W.,
Younkin, Steven,
Younkin, Linda,
Schiff, Richard,
Weksler, Marc E.
Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer’s disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Abeta). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. […]
CSF biomarker profile and diagnostic value in vascular dementia
Paraskevas, G. P.,
Kapaki, E.,
Papageorgiou, S. G.,
Kalfakis, N.,
Andreadou, E.,
Zalonis, I.,
Vassilopoulos, D.
Background and Purpose: The differential diagnosis between vascular dementia (VD) and Alzheimer’s disease (AD) or mixed dementia (MD) is not always easy in clinical practice. The purpose of the present study was to evaluate the cerebrospinal fluid (CSF) biomarkers tau protein in its total (tau(T)) or hyperphosphorylated at threonin-181(tau(P-181)) form and beta amyloid peptide 1-42 […]
Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients
Nordberg, Agneta,
Darreh-Shori, Taher,
Peskind, Elaine,
Soininen, Hilkka,
Mousavi, Malahat,
Eagle, Gina,
Lane, Roger
Background: The current study aimed to compare the effects of different cholinesterase inhibitors on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities and protein levels, in the cerebrospinal fluid (CSF) of Alzheimer disease (AD) patients.; Methods and Findings: AD patients aged 50-85 years were randomized to open-label treatment with oral rivastigmine, donepezil or galantamine for 13 weeks. […]
Voxel-based morphometry in individual patients: a pilot study in early Huntington disease
Mühlau, M.,
Wohlschläger, A. M.,
Gaser, C.,
Valet, M.,
Weindl, A.,
Nunnemann, S.,
Peinemann, A.,
Etgen, T.,
Ilg, R.
Background and Purpose: Voxel-based morphometry (VBM) has proved a powerful method to detect subtle changes of gray matter (GM) at the group level but the role of VBM for the detection of GM changes in single subjects, especially in those with suspected neurodegenerative disorder, remains uncertain. Here, we performed single subject analyses in 22 patients […]
Mobility training after hip fracture: a randomised controlled trial
Moseley, Anne M.,
Sherrington, Catherine,
Lord, Stephen R.,
Barraclough, Elizabeth,
St George, Rebecca J.,
Cameron, Ian D.
Objective: to compare the effects of two different exercise programmes after hip fracture.; Design: assessor-blinded randomised controlled trial.; Setting: hospital rehabilitation units, with continued intervention at home.; Subjects: 160 people with surgical fixation for hip fracture transferred to inpatient rehabilitation.; Method: in addition to other rehabilitation strategies, the intervention group received a higher dose (60 […]
Levodopa use and sleep in patients with dementia with Lewy bodies
Sleep disturbance and excessive daytime somnolence (EDS) are features of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) that may be influenced by dopamine replacement therapy. The effect of levodopa on sleep and EDS in DLB is unknown and unclear in PD. The aim of this study is to determine if levodopa treatment alters […]
Increase of BDNF serum concentration in lithium treated patients with early Alzheimer’s disease
Leyhe, Thomas,
Eschweiler, Gerhard W.,
Stransky, Elke,
Gasser, Thomas,
Annas, Peter,
Basun, Hans,
Laske, Christoph
Preclinical and clinical studies gave evidence that lithium could be useful in the treatment of Alzheimer’s disease (AD). In experimental investigations, lithium induces brain-derived neurotrophic factor (BDNF). Recent studies have found a decrease of BDNF in the serum and brains of AD patients with potentially consecutive lack of neurotrophic support. We assessed the influence of […]
Randomized controlled trial of memantine in dementia associated with Parkinson’s disease
The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson’s disease (PDD), an increasingly common complication of PD. This was a 22-week trial of 25 participants with a DSM-IV diagnosis of PDD who were randomized to either placebo or 20 […]